Page 219 - Read Online

Zhang et al. J Cancer Metastasis Treat 2018;4:16 I http://dx.doi.org/10.20517/2394-4722.2018.01 Page 11 of 11

24. Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW,
Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and
prognostic relevance of tumor-infltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Oncotarget 2015;6:40836-49.
25. Webb JR, Milne K, Nelson BH. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in
human ovarian cancer. Cancer Immunol Res 2015;3:926-35.
26. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination,
equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
27. Duchnowska R, Peksa R, Radecka B, Trojanwski T, Jarosz B, Olszewski WP, Och W, Kozłowski W, Kowalczyk A, Loi S, Biernat W,
Jassem J; Polish Brain Metastasis Consortium. Immune response in breast cancer brain metastases and their microenvironment: the
role of the PD-1/PD-L axis. Breast Cancer Res 2016;18:43-51.
28. Chen KY, Cheng GP, Zhang FR, Zhang N, Li D, Jin JY, Wu JZ, Ying LS, Mao WM, Su D. Prognostic significance of programmed death-1
and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:30772-80.
29. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-
infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013;139:667-76.
30. Sun L, Liu AL, Ku JW, Wei Y, Liu S, Zhang DY. Programmed death 1 expression on tumor tissues correlates with prognosis in
esophageal squamous cell carcinoma patients. Clin J Exp Surg 2015;32:1817-9.
31. Xu H, Lin G, Huang C, Zhu W, Miao Q, Fan X, Wu B, Zheng X, Lin X, Jiang K, Hu D, Li C. Assessment of concordance between
22C3 and SP142 immunohistochemistry assays regarding PD-L1 expression in non-small cell lung cancer. Sci Rep 2017;7:16956-
7034.
32. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
33. He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. PD-1, PD-L1 protein expression in non-small
cell lung cancer and their relationship with tumor-infiltrating lymphocyte. Med Sci Monit 2017;23:1208-16.
34. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Honjo T, Fujii S.
Programmed cell death 1 ligand1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci U S A 2007;104:3360-5.
35. Nakano O, Sato M, Naito Y, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral
CD8(+)T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
Cancer Res 2001;61:5132-6.
36. D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK.
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol
2015;46:357-65.
37. Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, Wu Z, Liu X, Lin Y, Zhang Z, Li J. Implication of combined PD-L1/PD-1 blockade
with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget 2016;7:10332-44.
38. Abdel RO. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
Immunotherapy 2016;8:1081-9.
39. Abdel RO. Correlation between PD-L1 expression and outcome of NSCLC patients treated with antiPD-1/PD-L1 agents: a meta-
analysis. Crit Rev Oncol Hematol 2016;101:75-85.